Propanc Biopharma files four patent applications, secures $100M facility

Propanc Biopharma Inc. (NASDAQ: PPCB) filed four provisional patent applications with IP Australia covering new treatment methods for resistant cancer and fibrosis, along with synthetic production methods for trypsinogen and chymotrypsinogen, according to a company statement.

The Melbourne-based biopharmaceutical company said the patents detail formulations of its proenzyme treatments. The company expects the applications to more than double its intellectual property portfolio from approximately 90 to over 200 patents across major global markets.

Propanc also published research findings in Scientific Reports regarding the impact of its proenzyme treatment PRP on pancreatic ductal adenocarcinoma fibroblasts. The study was conducted with research partners at the Universities of Jaén and Granada.

The company entered into a private placement agreement for up to $100 million to fund clinical development. Propanc received an initial $1 million investment through the issuance of 100 shares of Series C Convertible Preferred Stock, with an additional $500,000 received upon exercise of 50 shares.

For the quarter ended December 31, 2025, the company reported total assets of $15.11 million and quarter-end cash of $561,237. Total liabilities decreased by $2.07 million, while convertible notes were reduced to $55,000 from $538,000. The company received $3.49 million in net cash from financing activities during the quarter.

CEO James Nathanielsz said the company is preparing for a Phase 1b first-in-human study of PRP in advanced cancer patients. The company is partnering with GMP manufacturing and bio-analytical contract organizations for drug production and pharmacokinetics validation.

For the six-month period ended December 31, 2025, Propanc reported a net loss of $7.9 million compared to $784,493 in the same period of the prior year. The company reported no revenue for either period.

You May Also Be Interested In

• Bank of New York Mellon (BNY) call put ratio 1 call to 2 put into quarter results
• Carolina Rush names Patrick Quigley VP of exploration, grants equity
• Mizuho Reiterates Outperform Rating on Gulfport Energy (GPOR)